1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,730 | 1,750 | 11:43 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04:47 | JUNSHI BIO First Patient Dosed in Phase III Trial of JS207 Combined With JS007 for Advanced Hepatocellular Carcinoma | 1 | AASTOCKS | ||
| SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 03:47 | JUNSHI BIO 9M Loss Narrows to RMB149 Million | 1 | AASTOCKS | ||
| Do | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON CASH MANAGEMENT BY USING TEMPORARILY IDLE ... | 3 | HKEx | ||
| Do | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 2026 THIRD QUARTERLY REPORT | 3 | HKEx | ||
| Do | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE CONVENING OF THE 2026 THIRD QUARTERLY ... | 1 | HKEx | ||
| Do | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST PATIENT DOSING IN THE PHASE III CLINICAL TRIAL OF JS207 IN COMBINATION WITH JS007 FOR ... | 1 | HKEx | ||
| Do | Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination with JS007 for the First-Line Treatment of Advanced Hepatocellular Carcinoma | 433 | GlobeNewswire (Europe) | SHANGHAI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| Do | Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma | 476 | GlobeNewswire (Europe) | SHANGHAI, China, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated... ► Artikel lesen | |
| Mi | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE SUPPLEMENTAL NEW DRUG APPLICATION OF TORIPALIMAB INJECTION (SUBCUTANEOUS INJECTION) FOR ... | 1 | HKEx | ||
| Mi | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - REGULAR APPROVAL FOR TORIPALIMAB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ... | 2 | HKEx | ||
| Mi | Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026 | 473 | GlobeNewswire (Europe) | Perioperative toripalimab plus chemotherapy demonstrated significant and durable improvements in event-free survival and overall survival in patients with resectable stage II-III non-small cell lung... ► Artikel lesen | |
| Mo | JUNSHI BIO JS203 Combined With Chemotherapy Phase III Clinical Study Completes First Patient Dosing | 3 | AASTOCKS | ||
| Sa | Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma | 695 | GlobeNewswire (Europe) | SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated... ► Artikel lesen | |
| 23.10. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST PATIENT DOSING IN THE PHASE III CLINICAL TRIAL OF JS203 IN COMBINATION WITH CHEMOTHERAPY ... | - | HKEx | ||
| 24.09. | JUNSHI BIO (01877): 2026 INTERIM REPORT | 5 | HKEx | ||
| 23.09. | JUNSHI BIO (01877): RESERVED GRANT OF A SHARE OPTIONS, FULFILMENT OF THE EXERCISE CONDITIONS FOR THE FIRST EXERCISE PERIOD AND CANCELLATION OF CERTAIN ... | - | HKEx | ||
| 23.09. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE RESOLUTIONS OF THE TWENTY-THIRD MEETING ... | - | HKEx | ||
| 04.09. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE CONVENING OF THE 2026 INTERIM RESULTS ... | 2 | HKEx | ||
| 31.08. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE PLAN FOR THE REDUCTION IN THE SHAREHOLDING ... | - | HKEx | ||
| 27.08. | Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates | 695 | GlobeNewswire (Europe) | SHANGHAI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen |
1 2 3 4 Weiter >>
64 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 288,62 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| DISC MEDICINE | 82,84 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,840 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,200 | 0,00 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,235 | -0,12 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| KINIKSA PHARMACEUTICALS | 97,48 | -0,08 % | Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales | ||
| KYMERA THERAPEUTICS | 122,55 | 0,00 % | Oppenheimer raises Kymera Therapeutics price target on drug data | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 12,585 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial | Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab's 60 mg with... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,510 | 0,00 % | Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside? | ||
| RAPPORT THERAPEUTICS | 24,190 | 0,00 % | Rapport Therapeutics bricht ein: Großvolumige Kapitalerhöhung mit hohem Abschlag belastet Kurs | ||
| 4D MOLECULAR THERAPEUTICS | 12,780 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME | 4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 31,980 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints Rob Scott, MD to Board of Directors | ||
| COGENT BIOSCIENCES | 31,980 | 0,00 % | Stifel bekräftigt Kaufempfehlung für Cogent Biosciences nach ESMO-Daten | ||
| PRIME MEDICINE | 5,225 | -0,29 % | Prime Medicine, Inc.: Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease | -- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation... ► Artikel lesen | |
| ABSCI | 12,100 | 0,00 % | Jefferies nimmt Absci mit "Buy" auf - Potenzial bei Wirkstoff gegen Haarausfall im Fokus |
Das Unternehmen SHANGHAI JUNSHI BIOSCIENCES CO LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,070 (-3,89 %) liegt der Kurs bei 1,730 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI JUNSHI BIOSCIENCES CO LTD finden Sie auf Wallstreet Online.